These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21590794)

  • 1. Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations.
    Whitehead J; Thygesen H; Whitehead A
    Stat Med; 2011 Jul; 30(16):1952-70. PubMed ID: 21590794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
    Shimamura F; Hamada C; Matsui S; Hirakawa A
    J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.
    Thygesen H; Dragalin V; Whitehead A; Whitehead J
    Pharm Stat; 2012; 11(6):476-84. PubMed ID: 23011957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
    Wang Z; Zhang J; Xia T; He R; Yan F
    J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
    Thall PF; Cook JD; Estey EH
    J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.
    Zhong W; Koopmeiners JS; Carlin BP
    Stat Med; 2012 Dec; 31(29):3885-95. PubMed ID: 22807126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
    Cunanan K; Koopmeiners JS
    BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
    Wheeler GM; Sweeting MJ; Mander AP; Lee SM; Cheung YK
    Stat Med; 2017 Jan; 36(2):225-241. PubMed ID: 26891942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity.
    Whitehead J; Thygesen H; Whitehead A
    Stat Med; 2010 Jul; 29(17):1808-24. PubMed ID: 20658549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.
    Whitehead J; Thygesen H; Jaki T; Davies S; Halford S; Turner H; Cook N; Jodrell D
    Stat Med; 2012 Aug; 31(18):1931-43. PubMed ID: 22495759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
    Thall PF; Estey EH
    Stat Med; 1993 Jul; 12(13):1197-211. PubMed ID: 8210822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.